Business · India Bureau
Supreme Court seeks 16% price cap on essential medicines to curb markups
The Supreme Court has questioned the government on why maximum retail prices of critical drugs, including cancer medications, cannot be capped at 16 per cent above manufacturing costs. A two-judge bench expressed concern over the high markups currently allowed on life-saving medicines.
LSN India ·
A Supreme Court bench comprising Justices Vikram Nath and Sandeep Mehta has raised concerns about the substantial price markups on essential medicines and asked the Centre to explain its stance on imposing stricter price controls. The bench specifically questioned why the maximum retail price (MRP) of vital drugs such as cancer treatments could not be limited to a 16 per cent markup over base costs.
The judicial intervention highlights growing concerns about the affordability of critical medications in India, where patients often struggle to access life-saving treatments due to high prices. The bench's query suggests an examination of the current pricing structure that permits substantially higher markups on essential pharmaceuticals, potentially impacting accessibility for economically disadvantaged sections of the population.
The Centre is expected to respond to the court's concerns, potentially leading to a re-evaluation of the pricing framework for essential medicines. The case underscores the ongoing tension between ensuring pharmaceutical profitability and protecting patient access to affordable healthcare, a key policy challenge in India's healthcare ecosystem.
The Supreme Court's intervention comes as part of broader efforts to balance the interests of manufacturers with the need for equitable access to medicines. Any decision on price caps would require careful consideration of industry sustainability and the government's regulatory objectives in the pharmaceutical sector.